AGEN - Easy Long from Here

I have been closely following AGEN after their approval of the Shingrix Vaccine. After a couple years of shortage issues, sales this year should be killer (they are partnered with GSK). Look for more positive news to come in about their oncology pipeline as well.

Weekly MACD cross, volume picking up. 1st target 5.00, selling part of my position there and holding the rest until spring.